The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Janssen; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen; MSD
Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma.
 
Cora N. Sternberg
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; Medscape; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; UroToday
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Rosa Tambaro
No Relationships to Disclose
 
Consuelo Buttigliero
Consulting or Advisory Role - Janssen-Cilag
Speakers' Bureau - ipsen
 
Franco Morelli
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb; Pfizer; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Zsuzsanna Papai
No Relationships to Disclose
 
Margitta Retz
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Guy Faust
No Relationships to Disclose
 
Andres Felipe Cardona Zorrilla
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Merck Sharp & Dohme; Roche
 
Nuria Lainez
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche; Sanofi
 
Stefano Panni
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Olatz Etxaniz
No Relationships to Disclose
 
Laurence Krieger
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen-Cilag; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD; Pfizer
Speakers' Bureau - Astellas Pharma; Ipsen; Janssen-Cilag; MSD; Pfizer
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen-Cilag; MSD
 
Maria Jose José Mendez Vidal
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche
 
Maartje Los
No Relationships to Disclose
 
Sabine de Ducla
Employment - Celgene (I); Roche
Stock and Other Ownership Interests - Roche; Roche (I)
Travel, Accommodations, Expenses - Roche; Roche (I)
 
Simon Fear
Employment - Roche
 
Axel Stuart Merseburger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag